Scarica l'app Stockscreener
2.00
2.04%
0.04
Precedente Chiudi:
$1.96
Aprire:
$2.02
Volume 24 ore:
23.54M
Relative Volume:
2.31
Capitalizzazione di mercato:
$690.31M
Reddito:
$22,000
Utile/perdita netta:
$-173.76M
Rapporto P/E:
-2.6038
EPS:
-0.7681
Flusso di cassa netto:
$-109.53M
1 W Prestazione:
+6.38%
1M Prestazione:
+3.09%
6M Prestazione:
+40.85%
1 anno Prestazione:
+55.04%
Intervallo 1D:
$1.97
$2.08
Intervallo di 1 settimana:
$1.86
$2.10
Portata 52W:
$0.9842
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Nome
Allogene Therapeutics Inc
Settore
Industria
Telefono
(650) 457-2700
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.00 | 690.31M | 22,000 | -173.76M | -109.53M | -0.7681 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2026-04-10 | Ripresa | Jefferies | Buy |
| 2026-01-09 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Ripresa | Oppenheimer | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-08-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-28 | Reiterato | B. Riley Securities | Buy |
| 2021-10-20 | Iniziato | Cowen | Outperform |
| 2021-10-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-10-08 | Downgrade | Stifel | Buy → Hold |
| 2021-09-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Ripresa | Jefferies | Buy |
| 2021-05-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-01-26 | Aggiornamento | Stifel | Hold → Buy |
| 2020-12-10 | Ripresa | H.C. Wainwright | Buy |
| 2020-11-24 | Iniziato | BofA Securities | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-06-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-19 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Downgrade | SunTrust | Buy → Hold |
| 2020-04-13 | Iniziato | SunTrust | Buy |
| 2020-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-24 | Iniziato | Berenberg | Hold |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-05 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Neutral |
| 2019-05-23 | Iniziato | Stifel | Hold |
| 2019-03-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
ALLO: All proposals, including director elections and share increase, were approved without contest - TradingView
ALLO: All proposals passed, including director elections and share authorization increase - TradingView
Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allogene Therapeutics Inc (ALLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allogene Therapeutics Inc (ALLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease - Yahoo Finance
Allogene Therapeutics Inc (ALLO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Allogene Therapeutics Inc (ALLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN
Allogene Therapeutics Stock Surges on Optimistic Trial Results and Price Target Increase - timothysykes.com
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? - Yahoo Finance
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut - Barchart.com
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio - Insider Monkey
A pioneering founder is stepping down as CEO of his Bay Area company ahead of a major test - The Business Journals
CMO Roberts to succeed Chang as Allogene CEO - biocentury.com
Certain Restricted Stock Units of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
Certain Common Stock of Allogene Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
Allogene Therapeutics Names Zachary Roberts as New CEO - The Globe and Mail
Allogene Therapeutics, Inc. 8-K SEC Filing May 28, 2026: Company Details, Common Stock, and Exchange Information - Minichart
Allogene CEO to step down; Agios drug fails key test - BioPharma Dive
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Allogene Therapeutics (ALLO) Announces Leadership Transition - GuruFocus
Allogene Therapeutics names Zachary Roberts CEO in planned succession - MSN
Allogene Therapeutics names Zachary Roberts as new CEO By Investing.com - Investing.com South Africa
Allogene Therapeutics CEO David Chang Steps Down - marketscreener.com
Allogene Therapeutics announces planned CEO succession - marketscreener.com
Allogene Therapeutics names Zachary Roberts as new CEO - Investing.com
Zachary Roberts named Allogene President and CEO, David Chang stepping down - TradingView
Allogene Therapeutics (ALLO) elevates Zachary Roberts to CEO with major equity awards - Stock Titan
Allogene Therapeutics, Inc. Announces CEO Changes - marketscreener.com
Allogene Therapeutics (ALLO) Surges 6%: Can the Biotech Reclaim Key Resistance?On Balance Volume - thelegaladvocate.com
ALLO Stock Steadies As Cash Runway Extends To 2029 On Trial Progress - StocksToTrade
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Cancer cell therapy firm Allogene lines up three investor talks - Stock Titan
ALLO News | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Allogene Therapeutics posts narrower-than-expected loss in Q1 - MSN
Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment - Traders Union
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss - Investing.com UK
ALLO Technical Analysis | Trend, Signals & Chart Patterns | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Number of shareholders of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M - MSN
Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy - Traders Union
Citadel affiliates, Kenneth Griffin report stakes in Allogene (ALLO) - Stock Titan
Lynx1 amends 13G for Allogene Therapeutics (NASDAQ: ALLO) showing 0% stake - Stock Titan
Allogene Therapeutics | SCHEDULE 13G/A: Others - Moomoo
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $7 to $14 - Moomoo
Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):